REGN logo

Regeneron Pharmaceuticals, Inc.

REGN
Healthcare|Biotechnology|US
$904.35
+1.45 (+0.16%)
DCF Value
$2028.80
Tangible Book / Share
$316.45
Graham Number
$592.50
Cash / Share
$91.46

Financials

Financial Snapshot

Market Cap
$93.54B
Enterprise Value
$92.59B
Revenue (TTM)
$16.90B
Net Income (TTM)
$4.82B
Cash & Investments
$9.30B
Net Cash
$6.59B
Free Cash Flow (TTM)
$3.59B
Operating CF (TTM)
$4.61B
Debt/Equity
0.08

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$1.04B$1.41B$2.81B$3.21B$3.59B$5.69B$7.74B$10.84B$9.01B$8.61B$9.30B
Operating Cash Flow
$1.49B$1.31B$2.20B$2.43B$2.62B$7.08B$5.01B$4.59B$4.42B$4.98B$4.61B
Free Cash Flow
$974.0M$1.03B$1.81B$2.00B$2.00B$6.53B$4.42B$3.67B$3.66B$4.08B$3.59B
Capital Expenditure
-$511.9M-$272.6M-$383.1M-$429.6M-$614.6M-$551.9M-$590.1M-$926.4M-$755.9M-$898.4M-$1.02B
Financing Cash Flow
-$700.4M-$24.4M-$77.1M-$252.1M-$1.97B-$1.01B-$1.01B-$1.79B-$2.20B-$3.72B-$4.22B

R&D Spending

R&D (TTM)
$6.72B
R&D Intensity
39.8%
R&D Growth vs Prior
+14.9%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$4.86B$5.87B$6.71B$6.56B$8.50B$16.07B$12.17B$13.12B$14.20B$14.34B$16.90B
R&D Expense
$1.95B$1.93B$2.04B$2.24B$2.50B$2.62B$3.06B$3.99B$5.23B$5.85B$6.72B
R&D % of Revenue
40.1%32.9%30.4%34.2%29.4%16.3%25.1%30.4%36.8%40.8%39.8%
SG&A
$1.18B$1.32B$1.56B$1.34B$1.35B$1.82B$2.12B$2.54B$2.95B$2.70B$2.76B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$4.86B$5.87B$6.71B$6.56B$8.50B$16.07B$12.17B$13.12B$14.20B$14.34B$16.90B
Cost of Revenue
$404.4M$542.5M$582.3M$975.4M$1.36B$2.72B$1.71B$2.24B$1.97B$2.10B$2.40B
Gross Profit
$4.46B$5.33B$6.13B$5.58B$7.14B$13.35B$10.47B$10.87B$12.23B$12.24B$14.49B
R&D
$1.95B$1.93B$2.04B$2.24B$2.50B$2.62B$3.06B$3.99B$5.23B$5.85B$6.72B
SG&A
$1.18B$1.32B$1.56B$1.34B$1.35B$1.82B$2.12B$2.54B$2.95B$2.70B$2.76B
Operating Income
$1.33B$2.08B$2.53B$2.21B$3.58B$8.95B$5.39B$4.35B$3.99B$3.58B$4.99B
Interest Expense
$7.2M$25.1M$28.2M$30.2M$56.9M$57.3M$59.4M$73.0M$55.2M$43.8M$46.7M
Pretax Income
$1.33B$2.08B$2.55B$2.43B$3.81B$9.33B$4.86B$4.20B$4.78B$5.23B$5.69B
Net Income
$895.5M$1.20B$2.44B$2.12B$3.51B$8.08B$4.34B$3.95B$4.41B$4.50B$4.82B
EPS (Diluted)
7.7010.3421.2918.4630.5271.9738.2234.7738.3441.4845.26
EBITDA
$1.44B$2.25B$2.73B$2.67B$4.10B$9.67B$5.26B$4.69B$5.32B$5.82B$6.25B
Shares Out. (M)
116.30115.91114.80114.60115.10112.20113.50113.70115.10108.60105.60

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$535.2M$812.7M$1.47B$1.62B$2.19B$2.89B$3.11B$2.73B$2.49B$3.12B$3.66B
Short-Term Investments
$503.5M$596.8M$1.34B$1.60B$1.39B$2.81B$4.64B$8.11B$6.52B$5.49B$5.64B
Total Current Assets
$3.91B$5.60B$7.96B$7.69B$9.78B$14.01B$15.88B$19.48B$18.66B$18.02B$20.80B
Total Assets
$6.97B$8.76B$11.73B$14.81B$17.16B$25.43B$29.21B$33.08B$37.76B$40.56B$44.41B
Total Current Liabilities
$1.24B$1.14B$1.44B$2.10B$2.70B$3.93B$3.14B$3.42B$3.94B$4.37B$6.20B
Long-Term Debt
$0.00$0.00$0.00$0.00$1.98B$1.98B$1.98B$1.98B$1.98B$1.99B$1.99B
Total Liabilities
$2.52B$2.62B$2.98B$3.72B$6.14B$6.67B$6.55B$7.11B$8.41B$9.30B$10.91B
Stockholders' Equity
$4.45B$6.14B$8.76B$11.09B$11.03B$18.77B$22.66B$25.97B$29.35B$31.26B$33.50B
Retained Earnings
$1.75B$2.95B$5.25B$7.38B$10.89B$18.97B$23.31B$27.26B$31.67B$35.80B$39.47B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$1.49B$1.31B$2.20B$2.43B$2.62B$7.08B$5.01B$4.59B$4.42B$4.98B$4.61B
Capital Expenditure
-$511.9M-$272.6M-$383.1M-$429.6M-$614.6M-$551.9M-$590.1M-$926.4M-$755.9M-$898.4M-$1.02B
Free Cash Flow
$974.0M$1.03B$1.81B$2.00B$2.00B$6.53B$4.42B$3.67B$3.66B$4.08B$3.59B
Investing Cash Flow
-$1.05B-$1.01B-$1.46B-$2.03B-$70.6M-$5.38B-$3.78B-$3.19B-$2.47B-$629.1M-$589.4M
Financing Cash Flow
-$700.4M-$24.4M-$77.1M-$252.1M-$1.97B-$1.01B-$1.01B-$1.79B-$2.20B-$3.72B-$4.22B
Issuance of Stock
$126.7M$240.2M$114.5M$211.8M$2.58B$1.67B$1.52B$1.15B$1.47B$635.9M$1.02B
Repurchase of Stock
-$143.2M-$301.7M-$191.6M-$463.9M-$6.53B-$2.68B-$2.53B-$2.23B-$3.63B-$3.97B-$3.04B
Net Debt Issuance
-$40.6M$37.1M$0.00$0.00$1.98B$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$559.9M$507.3M$427.4M$464.3M$432.0M$601.7M$725.0M$885.0M$982.8M$993.7M$1.01B
Net Change in Cash
-$273.9M$277.5M$655.0M$150.1M$577.0M$690.8M$221.3M-$381.6M-$248.8M$634.7M-$200.2M

Dilution Tracker

Shares Outstanding
103M
5-Year Share Growth
-5.6%
Stock Issuance (TTM)
$1.02B
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
116.30115.91114.80114.60115.10112.20113.50113.70115.10108.60105.60
Change vs Prior %
—-0.3%-1.0%-0.2%0.4%-2.5%1.2%0.2%1.2%-5.6%-2.8%
Stock Issuance
$126.7M$240.2M$114.5M$211.8M$2.58B$1.67B$1.52B$1.15B$1.47B$635.9M$1.02B
Stock Repurchase
-$143.2M-$301.7M-$191.6M-$463.9M-$6.53B-$2.68B-$2.53B-$2.23B-$3.63B-$3.97B-$3.04B
Stock Based Comp.
$559.9M$507.3M$427.4M$464.3M$432.0M$601.7M$725.0M$885.0M$982.8M$993.7M$1.01B

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
91.7%90.8%91.3%85.1%84.0%83.1%86.0%82.9%86.1%85.4%85.8%
Operating Margin %
27.4%35.4%37.8%33.7%42.1%55.7%44.2%33.2%28.1%24.9%29.5%
Net Margin %
18.4%20.4%36.4%32.3%41.3%50.2%35.6%30.1%31.1%31.4%28.5%
EBITDA Margin %
29.7%38.3%40.7%40.7%48.3%60.2%43.2%35.8%37.4%40.6%37.0%
FCF Margin %
20.0%17.6%27.0%30.5%23.6%40.6%36.3%28.0%25.8%28.4%21.2%
ROE %
20.1%19.5%27.9%19.1%31.9%43.0%19.1%15.2%15.0%14.4%15.1%
ROA %
12.8%13.7%20.8%14.3%20.5%31.7%14.9%12.0%11.7%11.1%10.8%
ROIC %
13.6%13.5%20.6%15.1%22.8%34.9%18.4%13.8%10.9%8.5%10.9%
R&D / Revenue %
40.1%32.9%30.4%34.2%29.4%16.3%25.1%30.4%36.8%40.8%39.8%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
18.4%20.8%14.3%-2.3%29.6%89.1%-24.3%7.8%8.3%1.0%
Gross Profit
22.5%19.6%15.0%-8.9%27.9%86.9%-21.6%3.9%12.5%0.1%
Operating Income
6.3%56.3%21.9%-12.8%61.9%150.1%-39.8%-19.3%-8.2%-10.3%
Net Income
40.8%33.8%104.0%-13.4%66.0%129.9%-46.3%-8.9%11.6%2.1%
EPS (Diluted)
39.5%34.3%105.9%-13.3%65.3%135.8%-46.9%-9.0%10.3%8.2%
Operating Cash Flow
11.7%-12.0%67.9%10.7%7.7%170.5%-29.2%-8.4%-3.8%12.6%
Free Cash Flow
49.2%6.2%75.2%10.4%0.2%225.9%-32.2%-17.1%-0.1%11.3%
R&D Expense
26.0%-0.9%5.6%9.9%11.6%4.9%16.6%30.5%31.3%11.8%
SG&A Expense
40.4%12.1%17.9%-13.8%0.3%35.6%15.9%20.0%16.3%-8.6%
Total Assets
24.3%25.7%33.9%26.2%15.9%48.2%14.9%13.2%14.1%7.4%
Book Value / Share
20.7%38.5%43.9%33.1%0.9%73.3%19.2%15.0%11.8%9.8%
Debt
28.1%46.2%0.7%0.8%277.6%0.1%0.1%0.1%0.1%0.1%
Diluted Shares
0.9%-0.3%-1.0%-0.2%0.4%-2.5%1.2%0.2%1.2%-5.6%

Valuation

P/E (TTM)19.26
10Y Low / Med / High8.27 / 17.92 / 42.93
P/S5.54
10Y Low / Med / High4.15 / 6.35 / 8.78
P/B2.75
10Y Low / Med / High2.58 / 3.70 / 9.59
EV/EBITDA14.82
10Y Low / Med / High6.88 / 15.02 / 29.56
EV/Revenue5.48
10Y Low / Med / High4.14 / 6.28 / 8.77
P/FCF26.07
10Y Low / Med / High10.22 / 23.66 / 43.81

Intrinsic Value Models (per share)

DCF Value
$2028.80
Tangible Book / Share
$316.45
Net Current Assets / Share
$95.60
Graham Number
$592.50
Graham Net-Net
$54.33
Cash / Share
$91.46
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
42.9333.3617.5419.3714.808.2717.8123.7117.4217.9219.26
P/S Ratio
8.787.426.396.256.124.156.357.145.415.635.54
P/B Ratio
9.597.094.903.704.713.563.413.612.622.582.75
EV/EBITDA
29.5619.3315.4315.0212.796.8814.6119.9614.4913.8114.82
EV/Revenue
8.777.406.286.116.184.146.317.145.435.605.48

Analyst Estimates & Quality

Altman Z-Score
7.59
Safe
Piotroski F-Score
6
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$18.75B$20.10B$21.74B
Net Income$7.39B$7.54B$8.34B
EPS$67.55$70.32$77.93
# Analysts (EPS)15108

Dividends

Dividend/Share (TTM)
$3.70
Dividend Yield
0.41%
Frequency
Quarterly
Next Payment
Dec 3, 2026

Recent Payments

Ex-DatePay DateAmountFrequency
Nov 20, 2026Dec 3, 2026$0.94Quarterly
Aug 18, 2026Aug 31, 2026$0.94Quarterly
May 20, 2026Jun 4, 2026$0.94Quarterly
Feb 20, 2026Mar 5, 2026$0.94Quarterly
Nov 20, 2025Dec 5, 2025$0.88Quarterly
Aug 18, 2025Sep 3, 2025$0.88Quarterly
May 20, 2025Jun 6, 2025$0.88Quarterly
Feb 20, 2025Mar 20, 2025$0.88Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Product$5.57B$12.12B$6.89B$7.08B$7.63B$6.31B
Product and Service, Other—$281.2M$365.1M$536.1M$515.0M$702.6M
Collaboration Revenue——$2.06B$5.50B$6.06B$7.33B

By Geography

Segment2025
UNITED STATES$4.38B
Rest Of World$507.5M